{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:55:04Z","timestamp":1789577704768,"version":"build-2803163510"},"publisher-location":"New York, NY","reference-count":42,"publisher":"Springer US","isbn-type":[{"value":"9781071631744","type":"print"},{"value":"9781071631751","type":"electronic"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-1-0716-3175-1_24","type":"book-chapter","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T07:02:13Z","timestamp":1684479733000},"page":"369-380","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Assays to Monitor Bivalirudin"],"prefix":"10.1007","author":[{"given":"Simon","family":"Davidson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,20]]},"reference":[{"key":"24_CR1","doi-asserted-by":"publisher","first-page":"334","DOI":"10.2459\/JCM.0b013e32835f1915","volume":"14","author":"S De Servi","year":"2013","unstructured":"De Servi S, Mariani G, Mariani M, D\u2019Urbano M (2013) The bivalirudin paradox: high evidence, low use. J Cardiovasc Med 14:334\u2013341","journal-title":"J Cardiovasc Med"},{"key":"24_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.717835","volume":"29","author":"M Lund","year":"2021","unstructured":"Lund M, Macwan AS, Tunstr\u00f6mer K, Lindahl TL, Bokn\u00e4s N (2021) Effects of heparin and bivalirudin on thrombin-induced platelet activation: differential modulation of PAR signaling drives divergent prothrombotic responses. Front Cardiovasc Med 29:717835","journal-title":"Front Cardiovasc Med"},{"key":"24_CR3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1055\/s-0036-1597297","volume":"43","author":"EM Van Cott","year":"2017","unstructured":"Van Cott EM, Roberts AJ, Dager WE (2017) Laboratory monitoring of parenteral direct thrombin inhibitors. Semin Thromb Hemost 43:270\u2013276","journal-title":"Semin Thromb Hemost"},{"key":"24_CR4","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1160\/TH07-10-0644","volume":"99","author":"TE Warkentin","year":"2008","unstructured":"Warkentin TE, Greinacher A, Koster A (2008) Bivalirudin. Thromb Haemost 99:830\u2013839","journal-title":"Thromb Haemost"},{"key":"24_CR5","unstructured":"Medicines Agency 2016 Bivalirudin 250 mg powder for concentrate for solution for injection or infusion. http:\/\/www.medicinces.org.uk\/emc\/product\/7229\/smpc\/print. Accessed 26 Sept 2022"},{"key":"24_CR6","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1097\/MAT.0000000000001062","volume":"66","author":"A Bates","year":"2020","unstructured":"Bates A, Buchholz H, Freed D, MacArthur R, PiDBorochynski T, Conway J (2020) Bivalirudin experience in a heterogeneous ventricular assist device population. ASAIO J 66:677\u2013682","journal-title":"ASAIO J"},{"key":"24_CR7","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/ijlh.13780","volume":"44","author":"J Teruya","year":"2022","unstructured":"Teruya J, Bruzdoski K, Hensch L, Hui SR, Kostousov V (2022) How to best monitor bivalirudin anticoagulant effect for ECMO and VAD-comparison of four assay methods. Int J Lab Hematol 44:589\u2013594","journal-title":"Int J Lab Hematol"},{"key":"24_CR8","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1053\/j.jvca.2013.10.004","volume":"28","author":"F Pappalardo","year":"2014","unstructured":"Pappalardo F, Agracheva N, Covello RD, Pieri M, De Bonis M, Calabr\u00f2 MG, Koster A, Zangrillo A (2014) Anticoagulation for critically ill cardiac surgery patients: is primary bivalirudin the next step? J Cardiothorac Vasc Anesth 28:1013\u20131017","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"24_CR9","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1111\/jth.13057","volume":"13","author":"SH O\u2019Brien","year":"2015","unstructured":"O\u2019Brien SH, Yee DL, Lira J, Goldenberg NA, Young G (2015) UNBLOCK: an open-label, dose-finding, pharmacokinetic and safety study of bivalirudin in children with deep vein thrombosis. J Thromb Haemost 13:1615\u20131622","journal-title":"J Thromb Haemost"},{"key":"24_CR10","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1001\/jama.289.7.853","volume":"289","author":"AM Lincoff","year":"2003","unstructured":"Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ, REPLACE-2 Investigators (2003) Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289:853\u2013863","journal-title":"JAMA"},{"key":"24_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.amjcard.2004.05.068","volume":"94","author":"E Cheneau","year":"2004","unstructured":"Cheneau E, Canos D, Kuchulakanti PK, Rha SW, Satler LF, Suddath WO, Kent KM, Pichard AD, Waksman R (2004) Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention. Am J Cardiol 94:789\u2013792","journal-title":"Am J Cardiol"},{"key":"24_CR12","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.athoracsur.2006.09.038","volume":"83","author":"A Koster","year":"2007","unstructured":"Koster A, Dyke CM, Aldea G, Smedira NG, McCarthy HL 2nd, Aronson S, Hetzer R, Avery E, Spiess B, Lincoff AM (2007) Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 83:572\u2013577","journal-title":"Ann Thorac Surg"},{"key":"24_CR13","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1016\/S0003-4975(02)04125-5","volume":"74","author":"JC Vasquez","year":"2002","unstructured":"Vasquez JC, Vichiendilokkul A, Mahmood S, Baciewicz FA Jr (2002) Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery. Ann Thorac Surg 74:2177\u20132179","journal-title":"Ann Thorac Surg"},{"key":"24_CR14","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1213\/ANE.0000000000002613","volume":"126","author":"L Shore-Lesserson","year":"2018","unstructured":"Shore-Lesserson L, Baker RA, Ferraris VA, Greilich PE, Fitzgerald D, Roman P, Hammon JW (2018) The Society of Thoracic Surgeons, The Society of Cardiovascular Anesthesiologists, and The American Society of ExtraCorporeal Technology: clinical practice guidelines-anticoagulation during cardiopulmonary bypass. Anesth Analg 126:413\u2013424","journal-title":"Anesth Analg"},{"key":"24_CR15","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1213\/ANE.0000000000005721","volume":"133","author":"A Wanat-Hawthorne","year":"2021","unstructured":"Wanat-Hawthorne A, Tanaka K, Angona R, Feng C, Eaton M (2021) Survey of practice pattern in patients with heparin-induced thrombocytopenia requiring cardiopulmonary bypass. Anesth Analg 133:1180\u20131186","journal-title":"Anesth Analg"},{"key":"24_CR16","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jtcvs.2005.09.057","volume":"131","author":"CM Dyke","year":"2006","unstructured":"Dyke CM, Smedira NG, Koster A, Aronson S, McCarthy HL 2nd, Kirshner R, Lincoff AM, Spiess BD (2006) A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg 131:533\u2013539","journal-title":"J Thorac Cardiovasc Surg"},{"key":"24_CR17","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1309\/AJCPQOD9WFPEYY0H","volume":"138","author":"J Curvers","year":"2012","unstructured":"Curvers J, van de Kerkhof D, Stroobants AK, van den Dool EJ, Scharnhorst V (2012) Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful? Am J Clin Pathol 138:551\u2013558","journal-title":"Am J Clin Pathol"},{"key":"24_CR18","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1345\/aph.1D565","volume":"38","author":"RC Gosselin","year":"2004","unstructured":"Gosselin RC, King JH, Janatpour KA, Dager WE, Larkin EC, Owings JT (2004) Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing. Ann Pharmacother 38:1383\u20131388","journal-title":"Ann Pharmacother"},{"key":"24_CR19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1160\/TH06-10-0607","volume":"98","author":"JE Love","year":"2007","unstructured":"Love JE, Ferrell C, Chandler WL (2007) Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost 98:234\u2013242","journal-title":"Thromb Haemost"},{"key":"24_CR20","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","volume":"2","author":"A Cuker","year":"2018","unstructured":"Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y, Linkins LA, Rodner SB, Selleng S, Warkentin TE, Wex A, Mustafa RA, Morgan RL, Santesso N (2018) American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv 2:3360\u20133392","journal-title":"Blood Adv"},{"key":"24_CR21","first-page":"1063","volume":"5","author":"C Amiral","year":"2021","unstructured":"Amiral C, Dunois C, Amiral J (2021) Measurement of bivalirudin thrombin inhibition activity in plasma with clotting or chromogenic assays and dedicated calibrators and controls. Thromb Haemost Res 5:1063","journal-title":"Thromb Haemost Res"},{"key":"24_CR22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s11239-019-01961-3","volume":"49","author":"JT Beyer","year":"2020","unstructured":"Beyer JT, Lind SE, Fisher S, Trujillo TC, Wempe MF, Kiser TH (2020) Evaluation of intravenous direct thrombin inhibitor monitoring tests: correlation with plasma concentrations and clinical outcomes in hospitalized patients. J Thromb Thrombolysis 49:259\u2013267","journal-title":"J Thromb Thrombolysis"},{"key":"24_CR23","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1111\/ijlh.12319","volume":"37","author":"YA Kim","year":"2015","unstructured":"Kim YA, Gosselin R, Van Cott EM (2015) The effects of dabigatran on lupus anticoagulant, diluted plasma thrombin time, and other specialized coagulation assays. Int J Lab Hematol 37:e81\u2013e84","journal-title":"Int J Lab Hematol"},{"key":"24_CR24","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/ajh.25852","volume":"95","author":"RC Gosselin","year":"2020","unstructured":"Gosselin RC, Douxfils J (2020) Ecarin based coagulation testing. Am J Hematol 95:863\u2013869","journal-title":"Am J Hematol"},{"key":"24_CR25","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1177\/0961203314558859","volume":"24","author":"SM Mulliez","year":"2015","unstructured":"Mulliez SM, De Keyser F, Verbist C, Vantilborgh A, Wijns W, Beukinga I, Devreese KM (2015) Lupus anticoagulant-hypoprothrombinemia syndrome: report of two cases and review of the literature. Lupus 24:736\u2013745","journal-title":"Lupus"},{"key":"24_CR26","unstructured":"Sang Medicine Ltd. (2022). http:\/\/www.Practical-Haemostasis.com. Accessed 13 Oct 2022"},{"key":"24_CR27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s11239-017-1477-1","volume":"43","author":"KP Bliden","year":"2017","unstructured":"Bliden KP, Chaudhary R, Mohammed N, Muresan AA, Lopez-Espina CG, Cohen E, Raviv G, Doubleday M, Zaman F, Mathew B, Tantry US, Gurbel PA (2017) Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system. J Thromb Thrombolysis 43:437\u2013445","journal-title":"J Thromb Thrombolysis"},{"key":"24_CR28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1540-8191.2008.00604.x","volume":"23","author":"A Koster","year":"2008","unstructured":"Koster A, Buz S, Krabatsch T, Dehmel F, Hetzer R, Kuppe H, Dyke C (2008) Monitoring of bivalirudin anticoagulation during and after cardiopulmonary bypass using an ecarin-activated TEG system. J Card Surg 23:321\u2013323","journal-title":"J Card Surg"},{"key":"24_CR29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1177\/088506660201700103","volume":"17","author":"E Muhl","year":"2002","unstructured":"Muhl E, Siemens H-J, Kujath P, Bruch H-P (2002) Therapy and monitoring of heparin induced thrombocytopenia type II in critically ill patients during continuous venovenous hemodiafiltration: comparison of aPTT and ecarin clotting time for monitoring of r-hirudin therapy. J intensive Care Med 17:34\u201340","journal-title":"J intensive Care Med"},{"key":"24_CR30","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1055\/s-0038-1656078","volume":"77","author":"B P\u00f6tzsch","year":"1997","unstructured":"P\u00f6tzsch B, Madlener K, Seelig C, Riess CF, Greinacher A, M\u00fcller-Berghaus G (1997) Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass \u2013 assessment of the whole blood ecarin clotting time. Thromb Haemost 77:920\u2013925","journal-title":"Thromb Haemost"},{"key":"24_CR31","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000081506","volume":"33","author":"U Lange","year":"2003","unstructured":"Lange U, Nowak G, Bucha E (2003) Ecarin chromogenic assay \u2013 a new method for quantitative determination of direct thrombin inhibitors like hirudin. Pathophysiol Haemost Thromb 33:184\u2013191","journal-title":"Pathophysiol Haemost Thromb"},{"key":"24_CR32","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1309\/AJCPGTCEX7K4GXQO","volume":"141","author":"SE Lind","year":"2014","unstructured":"Lind SE, Boyle ME, Fisher S, Ishimoto J, Trujillo TC, Kiser TH (2014) Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples. Am J Clin Pathol 141:665\u2013674","journal-title":"Am J Clin Pathol"},{"key":"24_CR33","doi-asserted-by":"publisher","first-page":"e495S","DOI":"10.1378\/chest.11-2303","volume":"141","author":"LA Linkins","year":"2012","unstructured":"Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, Crowther M (2012) Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e495S\u2013e530S","journal-title":"Chest"},{"key":"24_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.565013","volume":"11","author":"H Zhong","year":"2020","unstructured":"Zhong H, Zhu ML, Yu YT, Li W, Xing SP, Zhao XY, Wang WJ, Gu ZC, Gao Y (2020) Management of bivalirudin anticoagulation therapy for extracorporeal membrane oxygenation in heparin-induced thrombocytopenia: a case report and a systematic review. Front Pharmacol 11:565013","journal-title":"Front Pharmacol"},{"key":"24_CR35","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1177\/0885066616656333","volume":"32","author":"F Sanfilippo","year":"2017","unstructured":"Sanfilippo F, Asmussen S, Maybauer DM, Santonocito C, Fraser JF, Erdoes G, Maybauer MO (2017) Bivalirudin for alternative anticoagulation in extracorporeal membrane oxygenation: a systematic review. J Intensive Care Med 32:312\u2013319","journal-title":"J Intensive Care Med"},{"key":"24_CR36","first-page":"267659121103431","volume":"28","author":"S Kaushik","year":"2021","unstructured":"Kaushik S, Derespina KR, Chandhoke S, Shah DD, Cohen T, Shlomovich M, Medar SS, Peek GJ (2021) Use of bivalirudin for anticoagulation in pediatric extracorporeal membrane oxygenation (ECMO). Perfusion 28:2676591211034314","journal-title":"Perfusion"},{"key":"24_CR37","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/j.1365-2125.2011.03916.x","volume":"72","author":"CJ Lee","year":"2011","unstructured":"Lee CJ, Ansell JE (2011) Direct thrombin inhibitors. Br J Clin Pharmacol 72:581\u2013592","journal-title":"Br J Clin Pharmacol"},{"key":"24_CR38","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/aor.12168","volume":"38","author":"M Pieri","year":"2014","unstructured":"Pieri M, Agracheva N, Di Prima AL, Nisi T, De Bonis M, Isella F, Zangrillo A, Pappalardo F (2014) Primary anticoagulation with bivalirudin for patients with implantable ventricular assist devices. Artif Organs 38:342\u2013346","journal-title":"Artif Organs"},{"key":"24_CR39","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.5858\/2004-128-1142-EOPFAD","volume":"128","author":"RC Gosselin","year":"2004","unstructured":"Gosselin RC, King JH, Janatpur KA, Dager WH, Larkin EC, Owings JT (2004) Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing. Arch Pathol Lab Med 128:1142\u20131145","journal-title":"Arch Pathol Lab Med"},{"key":"24_CR40","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/ajh.23867","volume":"89","author":"S Kadauke","year":"2014","unstructured":"Kadauke S, Khor B, Van Cott EM (2014) Activated protein C resistance testing for factor V Leiden. Am J Hematol 89:1147\u20131150","journal-title":"Am J Hematol"},{"key":"24_CR41","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1309\/7RYUN5DRK4WCH3PM","volume":"124","author":"JR Genzen","year":"2005","unstructured":"Genzen JR, Miller JL (2005) Presence of direct thrombin inhibitors can affect the results and interpretation of lupus anticoagulant testing. Am J Clin Pathol 124:586\u2013593","journal-title":"Am J Clin Pathol"},{"key":"24_CR42","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/MBC.0b013e32835e4219","volume":"24","author":"Y Xu","year":"2013","unstructured":"Xu Y, Wu W, Wang L, Chintala M, Plump AS, Ogletree ML, Chen Z (2013) Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro. Blood Coagul Fibrinolysis 24:332\u2013338","journal-title":"Blood Coagul Fibrinolysis"}],"container-title":["Methods in Molecular Biology","Hemostasis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-3175-1_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T07:06:06Z","timestamp":1684479966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-3175-1_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9781071631744","9781071631751"],"references-count":42,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-3175-1_24","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"20 May 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}